Loading stock data…
Keros Therapeutics (KROS)
$10.85-0.14 (-1.27%)
Market OpenUpdated 3:12 PM EDT
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Keros Therapeutics, Inc. in the Healthcare sector is trading at $10.85 with a market capitalization of $199M. Wall Street consensus targets $21.83 (6 analysts), implying a +101.2% move over the next 12 months. The stock is currently near its 52-week low of $9.69, remaining 26.8% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +101.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $367,000↓ | $385,000↓ | $14.26M↓ | $18.17M↓ | $211.25M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$25.88M↑ | -$29.27M↓ | -$15.38M↑ | -$39.82M↓ | $152.04M |
| Net Income | -$23.71M↓ | -$23.46M↓ | -$7.28M↑ | -$30.70M↓ | $148.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the U...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$199.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.81%
Volume
Today's trading volume
263,167
Recent News
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20
As you might know, Keros Therapeutics, Inc. ( NASDAQ:KROS ) last week released its latest first-quarter, and things did...